Results from a prospective real world study show strong efficacy of idelalisib in CLL, including high-risk CLL, and provide evidence that PJP prophylaxis positively impacts on overall survival. 26. Dezember 2018 Hoechstetter, M., Eissmann, P., Hucke, N., van Troostenburg, A., Ramroth, H., Knauf, W., 2018. Blood 132 (suppl 1), 4428. https://doi.org/10.1182/blood-2018-99-112843 Abstract Final results from IMPROVE: A randomized, controlled, open-label, cross-over phase IV study to determine the patients’ preference for either combined endocrine therapy (exemestane plus everolimus) or immunochemotherapy (capecitabine plus bevacizumab) as first line treatment for advanced HR+/HER2- breast cancer. Kurbacher, C., Söling, U., Hahn, A., Chiabudini, M., Maintz, C., Rieger, L., Falkenstein, J., Runkel, E., Potthoff, K., Decker, T., 2019. Cancer Res 79 (4… Weiterlesen Molecular testing, frequency of molecular alterations and targeted 1st-line treatment of patients with non-small cell lung carcinoma in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315) Griesinger, F., Eberhardt, W.E.E., Nusch, A., Reiser, M., Zahn, M.O., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert,… Weiterlesen